中基健康(000972) - 2024 Q1 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for Q1 2024 is projected to be between 5 million and 6.5 million yuan, representing a decrease of 70.38% to 61.50% compared to the same period last year, which was 16.8825 million yuan[6]. - The net profit after deducting non-recurring gains and losses is expected to be between 3.5 million and 5 million yuan, a decline of 79.07% to 70.10% from last year's 16.7219 million yuan[6]. - Basic earnings per share are forecasted to be between 0.0065 yuan and 0.0090 yuan, down from 0.0219 yuan per share in the same period last year[6]. Sales Performance - The primary reason for the decrease in profit is a 40% reduction in sales volume of the main product, large barrel tomato sauce, leading to a 45% decline in gross profit[7]. - Management, financial, and sales expenses remained relatively stable compared to last year, contributing to the overall decrease in net profit[7]. Audit and Disclosure - The performance forecast has not been audited by the accounting firm, but preliminary discussions indicated no significant discrepancies[6]. - The company emphasizes the importance of timely and accurate information disclosure to investors, urging caution in investment decisions[8].